Literature DB >> 20858839

Superior efficacy of tumor cell vaccines grown in physiologic oxygen.

Michael R Olin1, Brian M Andersen, David M Zellmer, Patrick T Grogan, Flavia E Popescu, Zhengming Xiong, Colleen L Forster, Charlie Seiler, Karen S SantaCruz, Wei Chen, Bruce R Blazar, John R Ohlfest.   

Abstract

PURPOSE: Atmospheric oxygen (∼20% O(2)) has been the universal condition employed to culture tumor cells used as vaccine antigen. We tested the hypothesis that reducing oxygen tension would increase the efficacy of tumor cell lysate vaccines. EXPERIMENTAL
DESIGN: GL261 glioma cells and EMT6 breast carcinoma cells were grown in 5% or 20% O(2). Syngeneic tumor-bearing mice were vaccinated with these tumor cell lysates mixed with CpG oligodeoxynucleotides as an adjuvant. Tumor infiltrating T cells and apoptotic GL261 cells were quantified by immunohistochemistry. Tumor-reactive immunoglobulin was detected by Western blot. Ovalbumin and gp100-derived peptides were mixed with GL261 lysates as marker antigens to detect changes in presentation of exogenous antigen on MHC class I in vitro, and in vivo following adoptive transfer of gp100-specific CD8(+) T cells.
RESULTS: Mice bearing orthotopic glioma and breast carcinoma survived significantly longer when vaccinated with 5% O(2) lysates. Antigen-specific CTL activation was significantly enhanced following stimulation with lysates derived from GL261 cells grown in 5% O(2) versus 20% O(2) through a mechanism that involved enhanced cross-presentation of exogenous antigen on MHC I. Vaccination with 5% O(2) GL261 cell lysates caused a significant increase in CTL proliferation, tumoricidal function, and trafficking into brain tumor sites, whereas 20% O(2) lysate vaccines predominantly evoked an antibody response.
CONCLUSIONS: Tissue culture oxygen functions as an "immunologic switch" by dictating the cellular and humoral immune responses elicited by tumor cell lysates. These results have profound implications for cancer vaccines that utilize tumor cells as the source of antigen. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858839      PMCID: PMC3016438          DOI: 10.1158/1078-0432.CCR-10-1572

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

Authors:  A B Lyons
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

2.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

Authors:  A Porgador; J W Yewdell; Y Deng; J R Bennink; R N Germain
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

3.  The first 1000 dendritic cell vaccinees.

Authors:  Derry Ridgway
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

4.  Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

Authors:  Robert M Prins; Sylvia K Odesa; Linda M Liau
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

Review 5.  Targeting the hypoxia-inducible factor (HIF) pathway in cancer.

Authors:  Evon Poon; Adrian L Harris; Margaret Ashcroft
Journal:  Expert Rev Mol Med       Date:  2009-08-27       Impact factor: 5.600

6.  Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.

Authors:  Amy M McCord; Muhammad Jamal; Uma T Shankavaram; Uma T Shankavarum; Frederick F Lang; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

7.  T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.

Authors:  Michail V Sitkovsky
Journal:  Trends Immunol       Date:  2009-02-07       Impact factor: 16.687

8.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

Review 9.  Modulation of adaptive immunity with Toll-like receptors.

Authors:  Santhakumar Manicassamy; Bali Pulendran
Journal:  Semin Immunol       Date:  2009-06-06       Impact factor: 11.130

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  19 in total

Review 1.  Increasing the efficacy of tumor cell vaccines by enhancing cross priming.

Authors:  Brian M Andersen; John R Ohlfest
Journal:  Cancer Lett       Date:  2012-07-16       Impact factor: 8.679

2.  Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.

Authors:  Zhengming Xiong; Elisabet Ampudia-Mesias; Rob Shaver; Craig M Horbinski; Christopher L Moertel; Michael R Olin
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 3.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 4.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

5.  Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.

Authors:  Michael Chae; Timothy E Peterson; Alexis Balgeman; Selby Chen; Lei Zhang; Danielle N Renner; Aaron J Johnson; Ian F Parney
Journal:  Neuro Oncol       Date:  2014-12-23       Impact factor: 12.300

6.  Oxygen is a master regulator of the immunogenicity of primary human glioma cells.

Authors:  Michael R Olin; Brian M Andersen; Adam J Litterman; Patrick T Grogan; Aaron L Sarver; Paul T Robertson; Xueqing Liang; Wei Chen; Ian F Parney; Matthew A Hunt; Bruce R Blazar; John R Ohlfest
Journal:  Cancer Res       Date:  2011-09-09       Impact factor: 12.701

7.  An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas.

Authors:  Katherine A Murphy; Melissa G Lechner; Flavia E Popescu; Jessica Bedi; Stacy A Decker; Peisheng Hu; Jami R Erickson; M Gerard O'Sullivan; Lauryn Swier; Andres M Salazar; Michael R Olin; Alan L Epstein; John R Ohlfest
Journal:  Clin Cancer Res       Date:  2012-07-10       Impact factor: 12.531

8.  Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Authors:  John R Ohlfest; Brian M Andersen; Adam J Litterman; Junzhe Xia; Christopher A Pennell; Lauryn E Swier; Andres M Salazar; Michael R Olin
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

9.  Hypoxia induces immunogenic cell death of cancer cells by enhancing the exposure of cell surface calreticulin in an endoplasmic reticulum stress-dependent manner.

Authors:  Yu Kyeong Han; Ga-Young Park; Min Ji Bae; Joong Sun Kim; Wol Soon Jo; Chang Geun Lee
Journal:  Oncol Lett       Date:  2019-10-14       Impact factor: 2.967

10.  Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring.

Authors:  Anthony E Rizzardi; Arthur T Johnson; Rachel Isaksson Vogel; Stefan E Pambuccian; Jonathan Henriksen; Amy Pn Skubitz; Gregory J Metzger; Stephen C Schmechel
Journal:  Diagn Pathol       Date:  2012-06-20       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.